NEW YORK, April 11, 2014 /PRNewswire/ -- Navidea
Pharmaceuticals, Inc. (NYSEMKT: NAVB), is a biopharmaceutical
company that is focused on the development and commercialization of
precision diagnostics and radiopharmaceutical agents. Its
core product, Lymphoseek, a small-molecule radiopharmaceutical used
in lymphatic mapping procedures, helps physician identify and
target the lymph nodes that drain from a primary tumor that contain
cancer cells.
The U.S. Food and Drug Administration, in March 2013 approved the use of Lymphoseek in
lymphatic mapping to assist in the localization of lymph nodes
draining a primary tumor in patients with breast cancer or
melanoma. Subsequently, the company, and its partner,
Cardinal Health Inc.'s Nuclear Pharmacy Services division, launched
Lymphoseek in the United States in
May 2013.
Navidea expects to receive approval for using Lymphoseek in
additional indications in U.S, including head and neck cancer,
later in the year. The company also anticipates that it will
obtain approval sell the product in Europe in 2014 and, then launch it in the
major European markets in 2015.
These potential positive regulatory milestones do not alter the
basic belief that Lymphoseek is a "niche product" whose potential
is more than limited than what is being projected by the sell-side
analyst community. The analyst report will provide further
information with respect to the anticipated potential of Lymphoseek
as well as discuss the key attribute of the product, provide an
overview of the company, and review financial results for fiscal
2013. There is no cost required to view this report:
http://bit.ly/NAVB-CFA-Report
copy and paste to browser may be required
Disclaimer:
The information contained herein is not intended to be
investment advice and does not constitute any form of invitation or
inducement by Paul Bienstock, CFA
and Money by Maggi to engage in investment activity. Neither the
information nor any opinion expressed constitutes a solicitation
for the purchase or sale of any security. Securities, financial
instruments, strategies, or commentary mentioned herein may not be
suitable for all investors and this material is not intended for
any specific investor and does not take into account an investor's
particular investment objectives, financial situations or needs.
Any opinions expressed herein are given in good faith, are subject
to change without notice, and are only current as of the stated
date of their issue. Prices, values, or income from any securities
or investments mentioned in this report may fluctuate, and an
investor may, upon selling an investment lose a portion of, or the
entire principal amount invested. Past performance is no guarantee
of future results. Before acting on any recommendation in this
material, you should consider whether it is suitable for your
particular circumstances and, if necessary, seek professional
advice.
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is written and authored by
Paul Bienstock, CFA. An outsourced
research services provider represented by Paul Bienstock, CFA, provided Small Cap Street,
LLC this article or report. However, we are only human and are
prone to make mistakes. If you notice any errors or omissions,
please notify us below. Small Cap Street, LLC and BrokerBank
Securities, Inc. are not entitled to veto, interfere or alter the
articles, documents or report once created and reviewed by the
outsourced research provider represented by Paul Bienstock, CFA.
If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at admin@smallcapir.com. For any urgent concerns or inquiries,
please contact us at admin@smallcapstreet.com.
NO WARRANTY OR LIABILITY ASSUMED
NAVB has not compensated Small Cap Street, LLC, BrokerBank
Securities, Inc., or Paul Bienstock,
CFA for the creation or dissemination of this report. Small Cap
Street, LLC and BrokerBank Securities, Inc., is not responsible for
any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. Small Cap Street,
LLC and BrokerBank Securities, Inc. do not hold any positions in
NAVB. No liability is accepted by Small Cap Street, LLC and
BrokerBank Securities, Inc. whatsoever for any direct, indirect or
consequential loss arising from the use of this document. Small Cap
Street, LLC and BrokerBank Securities, Inc. expressly disclaims any
fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Small Cap Street, LLC and BrokerBank
Securities, Inc. do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
Small Cap Street, LLC is the party responsible for hosting the
full analyst report. BrokerBank Securities in the party responsible
for issuing the press release and Paul
Bienstock, CFA, is the author of research report. Small Cap
Street, LLC has compensated Paul
Bienstock, CFA two hundred
dollars and fifty dollars for
the right to disseminate this report. BrokerBank Securities has
been compensated one hundred dollars
to issue press release by Small Cap Street, LLC. Information in
this release is fact checked and produced on a best efforts basis
by Paul Bienstock, CFA.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial
Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.